The latest price target for Oruka Therapeutics (NASDAQ:ORKA) was reported by HC Wainwright & Co. on December 20, 2024. The analyst firm set a price target for $45.00 expecting ORKA to rise to within 12 months (a possible 222.12% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Oruka Therapeutics (NASDAQ:ORKA) was provided by HC Wainwright & Co., and Oruka Therapeutics reiterated their buy rating.

There is no last upgrade for Oruka Therapeutics

There is no last downgrade for Oruka Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oruka Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oruka Therapeutics was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Oruka Therapeutics (ORKA) rating was a reiterated with a price target of $45.00 to $45.00. The current price Oruka Therapeutics (ORKA) is trading at is $13.97, which is out of the analyst’s predicted range.